The Brief Brief Science
what we just learned about everything.
Science — briefly, then briefly again · tbb.ceo
listen tothe daily 0:00 –:––
/daily ·26 OCT 2026 ·MONDAY ·2 MIN READ ·6 STORIES

The day in AI

01 / The Day

MONDAY 26 OCT 2026, ranked

06

Triple Black Hole System Found 12.5 Billion Light-Years Away

Astronomers discovered three actively-feeding supermassive black holes within a single galaxy located 12.5 billion light-years away, offering rare evidence of rapid multi-body galactic mergers in the very early universe.

  • Galaxy sits at redshift z=5.02, just 1.3 billion years after the Big Bang
  • All three black holes appear to be actively accreting simultaneously
  • Challenges models of how quickly galaxies can merge in the early cosmos
Why it mattersA triple-AGN system this early in cosmic history pushes the limits of galaxy formation theory and may require revised merger timescale models.
01 sciencedaily.com↗

RIKEN Achieves 99.9% Fidelity Across 5 Silicon Spin Qubits

Physicists at RIKEN demonstrated simultaneous operation of five silicon spin qubits on a single shared microwave control line with approximately 99.9% gate fidelity, suppressing the crosstalk errors that have blocked semiconductor quantum processor scaling.

  • 5 qubits controlled simultaneously via one shared microwave line
  • ~99.9% two-qubit gate fidelity achieved despite shared-line architecture
  • Silicon spin qubits are considered more manufacturable than superconducting alternatives
Why it mattersShared control lines eliminate the wiring overhead that has long made scaling silicon quantum chips impractical, making this a key step toward millions of physical qubits.
02 sciencedaily.com↗

Mushroom Behind Tiny-People Hallucinations Works Like No Other

University of Utah researchers identified Lanmaoa asiatica as the wild mushroom causing vivid hallucinations of miniature human figures, acting through a mechanism entirely distinct from psilocybin.

  • Compound induces perceptions of miniaturised humans (Lilliputian hallucinations)
  • Mechanism is entirely distinct from psilocybin or any known serotonergic pathway
  • Opens a new chemical class for potential neuropsychiatric and neuroscience research
Why it mattersA wholly new psychedelic mechanism in a widely-distributed fungus is both a neuropharmacology milestone and evidence that novel pharmacology remains hidden in common species.
03 sciencedaily.com↗

Microplastics Found to Spontaneously Generate Cell-Damaging ROS

Research published in Nature reveals that waterborne microplastics spontaneously generate reactive oxygen species (ROS), providing the first direct biophysical mechanism explaining how plastic particles cause DNA mutations and oxidative stress.

  • Plastic particles in water emit reactive oxygen species without any biological catalyst
  • ROS directly explains microplastic-induced DNA mutations and oxidative stress in tissues
  • Moves the evidence base from epidemiological correlation to established mechanism
Why it mattersEstablishing causation for microplastic harm is the crucial regulatory threshold — this mechanism finding opens a direct path to policy action and medical countermeasures.
04 nature.com↗

Blood Biomarker Predicts Complete Response in Lung Immunotherapy

The NeoCOAST-2 trial published in Nature found that early clearance of circulating tumour DNA (ctDNA) during neoadjuvant immunotherapy strongly predicts pathological complete response and extended survival in resectable non-small cell lung cancer.

  • ctDNA clearance predicts pCR non-invasively, avoiding repeat surgical biopsies
  • Early-clearance patients showed significantly longer event-free survival
  • Enables real-time treatment decisions mid-course before surgery
Why it mattersA validated blood-based response predictor transforms how clinicians can tailor lung cancer immunotherapy decisions mid-treatment without waiting for a surgical specimen.
05 doi.org↗

Bispecific DLL3 Antibody Sets New Bar in Small-Cell Lung Cancer

Adding the DLL3-targeting bispecific T-cell engager tarlatamab to first-line durvalumab maintenance produced the largest survival improvement ever recorded in extensive-stage small-cell lung cancer.

  • Tarlatamab targets DLL3, highly expressed in small-cell lung tumours
  • Both PFS and OS improved significantly versus durvalumab maintenance alone
  • SCLC has historically been extremely resistant to treatment beyond first-line therapy
Why it mattersSCLC is one of the deadliest and least-treatable cancers — a bispecific antibody that meaningfully improves overall survival in first-line maintenance is a landmark oncology result.
06 doi.org↗
Be subscriber #022 the weekly ten, every friday by email · no spam · unsubscribe anytime
Past days

The Daily Archive

/FRI 30 OCTIce, Warming, and a New Form of Magnetism/THU 29 OCTThree Natures, one missing comet, and the worst CTE numbers yet/WED 28 OCTWednesday: Malaria, Methane, and Mind/TUE 27 OCTThe Fungus, the Wreck, and the Spinning Earth/MON 26 OCT2026-10-26/SUN 25 OCTOld cells, new tricks/SAT 24 OCTPersonalised medicine had a good weekend/FRI 23 OCTIce Age Interrupted/THU 22 OCTLanguage meets biology at the bench/WED 21 OCTWednesday: A Proof Falls, a Universe Measures Itself/TUE 20 OCTQuantum ceiling hit, Bennu cracked, DNA rewritten on purpose/MON 19 OCTMonday's Mix: Quantum Frontiers and Inert No More/SUN 18 OCTClose Encounters/SAT 17 OCTScale Laws and Invisible Carbon/FRI 16 OCTCorals, Clocks, and Voices/THU 15 OCTThe Science Brief — October 15, 2026/WED 14 OCTShields, Plasticity, and Topologies/TUE 13 OCTTuesday dispatch/MON 12 OCTLava atmospheres, early humans, and a volcanic mystery solved/SUN 11 OCTWhat we just found/SAT 10 OCTSaturday Lab Notes